Value of Chemokine Receptor CXCR4-targeting Molecular Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Who is this study for? Adult patients with Lymphoma, Leukemia, or Multiple Myeloma
What treatments are being studied? 68-Gallium Pentixafor
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• suspected or confirmed untreated Lymphoproliferative diseases patients
• 18F-FDG PET/CT within two weeks
• signed written consent.
Locations
Other Locations
China
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITING
Fuzhou
Contact Information
Primary
Weibing Miao, M.D.
miaoweibing@126.com
+86-599-87981618
Backup
Zhenying Chen
chenzhenying726@foxmail.com
+86-599-87981619
Time Frame
Start Date: 2020-08-07
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 50
Treatments
Experimental: 68Ga-Pentixafor, PET/CT
PET/CT perform after injecting 68Ga-Pentixafor
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Fujian Medical University